| Nov 18 |
Inhibikase Therapeutics files for secondary offering of common stock
|
| Nov 14 |
Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17
|
| Nov 14 |
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
|
| Oct 23 |
Inhibikase Therapeutics Secures Funding and Strengthens Leadership
|
| Oct 18 |
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc
|
| Oct 9 |
Inhibikase Therapeutics Prices $110 Million Private Placement; Shares Jump
|
| Oct 9 |
Inhibikase Therapeutics stock rises after pricing $110M private offering
|
| Oct 9 |
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
|
| Aug 7 |
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
|
| Jun 18 |
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
|
